skip to main content

    Updated Visitor Guidelines

 

MENU

 

Why don't all types of renal cell carcinoma respond to immunotherapy?

By sequencing the RNA of individual cells within multiple benign and cancerous kidney tumors, researchers have identified the cells from which different subtypes originate, the pathways involved and how the tumor microenvironment impacts cancer development and response to treatment.

A new blood test may predict whether metastatic HPV-positive throat cancer treatment is working

A blood test being developed by Rogel Cancer Center researchers shows promise for predicting whether patients with metastatic HPV-positive throat cancer will respond to treatment earlier than standard scans.

First inhibitors against key epigenetic complex involved in cancer developed

Leukemia stem cells are rare cells that can renew themselves while continuing to generate malignant cells known as leukemic blasts. These cells are difficult to eradicate using chemotherapy drugs and frequently lead to recurrence of leukemia.

A new preclinical study examines how to counter lineage plasticity in prostate cancer

While patient survival has been extended by modern drugs that block the production or action of male hormones that fuel prostate cancer — androgen receptor inhibitors such as enzalutamide, apalutamide, darolutamide, and abiraterone — eventually these drugs stop working

Rogel Cancer Center members volunteer to administer COVID-19 vaccinations at local church

The Washtenaw County vaccination program has been offering COVID-19 vaccines to our community by partnering with local institutions like to sponsor events.

Rogel researcher gets $2.26M to undercover barriers to offering targeted cancer therapies

A $2.26 million grant from the National Cancer Institute lets Christine Veenstra, M.D., MSHP, study the barriers to equitable use of targeted therapies among diverse patients and diverse practice settings.

Thomas Collet, Ph.D.

Thomas Collet, Ph.D., is an experienced senior business leader and strategic thinker with a passion for innovation. Based in Cambridge, Mass., he specializes in helping firms in the life science and medical industries develop and commercialize new products and technologies. “I look for companies working on products that, if successful, will make a material difference in people’s lives,” he says.

Excessive radiation treatments for bone metastases reduced by 80% at University of Michigan

The two-year project focused on reducing the use of extended-fraction radiation therapy to treat pain from incurable cancer that had spread to patients’ bones. Once a standard practice, the American Society for Radiation Oncology has recommended against the routine use of extended-fraction radiation to relieve pain from bone metastases, especially more than 10 treatments.

Pages